Aromatic-Cationic Peptide Structure for CD36 Expression Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Abnormal expression of CD36 has been implicated in various diseases and conditions, necessitating a method to reduce its expression effectively.
Innovation Solution
Administration of aromatic-cationic peptides with specific charge and aromatic group ratios to cells or mammals to decrease CD36 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD36 expression is reduced, then therapeutic benefits are achieved in diseases characterized by abnormal CD36 expression, but the mechanism to achieve this reduction was not previously known
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of peptides to create aromatic-cationic compounds with specific properties (aromatic groups, cationic charges, specific ratios). These parameter changes enable the peptides to selectively interact with and reduce CD36 expression, providing a controllable mechanism for therapeutic effect.
Solution Approach 2:
The aromatic-cationic peptides serve as intermediary substances that mediate between the administration system and the CD36 protein. These peptides act as carriers that can penetrate cell membranes and deliver therapeutic effects by reducing CD36 expression, thereby simplifying the overall therapeutic mechanism.
2Reliability
If aromatic-cationic peptides are administered to reduce CD36 expression, then therapeutic effects are achieved, but the peptides must meet specific structural requirements (charge-to-size ratio, aromatic group content)
Solution Approach 1:
The patent establishes specific parameter ranges for peptide synthesis (aromatic group content, cationic charge density, peptide length) that optimize CD36 reduction while maintaining manufacturability. By defining these parameters, the synthesis process becomes more standardized and controllable.
Solution Approach 2:
The aromatic-cationic peptide structure is designed to be universally effective across different cell types and disease models. The same structural principles (aromatic groups, cationic charges) apply to reducing CD36 expression in various conditions, simplifying the development process.
3Reliability
If the peptide sequence is optimized for CD36 binding, then expression reduction is enhanced, but the peptide stability and pharmacokinetics must also be considered
Solution Approach 1:
The patent optimizes peptide parameters (sequence, structure, charge distribution) to balance CD36 binding affinity with stability. Specific parameter adjustments ensure the peptides remain stable in biological systems while maintaining high affinity for CD36, extending their duration of action.
Data Source
AI summary
The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.